Early trials for 'common cold' vaccine offer encouraging signs
A vaccine designed to protect against rhinoviruses, which cause the great majority of common colds and exacerbate chronic respiratory illnesses, has shown encouraging early results in a phase 1 clinical trial. Initial findings from the study showed that the vaccine candidate (APL-10456) was well tolerated in healthy volunteers and induced immunity against multiple rhinovirus species.
A vaccine against the common cold, caused by the rhinovirus, has demonstrated promising early results in a phase 1 clinical trial. The vaccine, known as APL-10456, was found to be well tolerated and successfully induced immunity against multiple rhinovirus species during the initial stages of the study. Developed through a collaboration between Imperial College London and Apollo Therapeutics, the vaccine's development has been years in the making, given the challenge of targeting the many different strains of rhinovirus that circulate worldwide.
Rhinoviruses are responsible for most common colds and can exacerbate chronic respiratory illnesses like asthma and COPD, placing a significant burden on patients and healthcare systems. Despite the ongoing efforts to develop targeted antiviral therapies and vaccines, none have been approved for rhinovirus infection. The phase 1 trial, involving 144 healthy participants, has completed enrollment and dosing.
The results indicate that a single dose of APL-10456 was safe and effective, eliciting immune responses against all three major rhinovirus species. The next step is a phase 2 trial, which will evaluate the vaccine's efficacy in preventing infections or reducing exacerbations in individuals with asthma, COPD, and other respiratory conditions.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
